Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Savara, Inc. - Common Stock (NQ:SVRA)

2.370 +0.090 (+3.95%)
Streaming Delayed Price Updated: 10:15 AM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 360,771
Open 2.390
Bid (Size) 2.360 (17)
Ask (Size) 2.370 (7)
Prev. Close 2.280
Today's Range 2.300 - 2.410
52wk Range 2.255 - 5.110
Shares Outstanding 114,066,080
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Starbucks Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-22.8%
-22.8%
1 Month
-25.7%
-25.7%
3 Month
-10.6%
-10.6%
6 Month
-30.5%
-30.5%
1 Year
-42.9%
-42.9%

More News

Read More
Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?
Via Benzinga
Exposures Product Safety
Here are the top movers in Tuesday's session.
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Via Chartmill
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April
Via Benzinga
Topics Stocks
Exposures US Equities
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara Announces Participation in Jefferies Global Healthcare Conference
From Savara Inc.
Via Business Wire
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025
From Savara Inc.
Via Business Wire
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update
From Savara Inc.
Via Business Wire
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference
From Savara Inc.
Via Business Wire
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
From Savara Inc.
Via Business Wire
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
From Savara Inc.
Via Business Wire
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
From Savara Inc.
Via Business Wire

Frequently Asked Questions

Is Savara, Inc. - Common Stock publicly traded?
Yes, Savara, Inc. - Common Stock is publicly traded.
What exchange does Savara, Inc. - Common Stock trade on?
Savara, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Savara, Inc. - Common Stock?
The ticker symbol for Savara, Inc. - Common Stock is SVRA on the Nasdaq Stock Market
What is the current price of Savara, Inc. - Common Stock?
The current price of Savara, Inc. - Common Stock is 2.370
When was Savara, Inc. - Common Stock last traded?
The last trade of Savara, Inc. - Common Stock was at 06/02/25 10:15 AM ET
What is the market capitalization of Savara, Inc. - Common Stock?
The market capitalization of Savara, Inc. - Common Stock is 270.34M
How many shares of Savara, Inc. - Common Stock are outstanding?
Savara, Inc. - Common Stock has 270M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.